Variation in clinical practice and its effect on outcome is little known for rare diseases such as primary antibody deficiency. As part of a national audit a survey of all 30 consultant immunologists in the United Kingdom dealing with primary antibody deficiency syndromes in adults and children was carried out in 1993 to ascertain their practices in diagnosis and management. Consensus guidelines were published after the survey was completed. Comparison of the survey results of clinical practice at the time the guidelines were published with the standards identified highlighted that the practice of a minority of specialists was at variance with their peers and with the consensus document, particularly in the use of intramuscular immunoglobulin, the dose and frequency of intravenous immunoglobulin, and target trough immunoglobulin G concentration, which has implications for the quality of patient care. However, much closer agreement existed in the key areas of management, such as diagnosis and selection of intravenous immunoglobulin. The approach and the problems identified are relevant to the management of other rare diseases, in which diagnosis and management is complex and there are few specialists with the necessary knowledge to undertake such care. This survey, the first attempted audit of practice, shows that within a motivated group of specialists highly significant differences in practice may exist, and the authors emphasise the importance of setting clear guidelines against which care can be assessed.
which is summarised in the following box.
As part of a national audit of the quality of care received by patients with antibody deficiency, it was thought to be important to ascertain the views of the immunologists managing such patients and to compare existing practice with the standards in the consensus document. If specialists with a particular interest in these conditions are not agreed on the optimum approach then it will be difficult to convince non-specialists of the correct management approach. The problems Primary antibody deficiency syndromes are rare disorders leading to the failure to produce adequate levels of protective antibodies.'
Although some are inherited, such as X linked agammaglobulinaemia, and present early in childhood, others are of uncertain aetiology and can present at any age, such as common variable immunodeficiency. The clinical presentation is usually with recurrent bacterial infections, although autoimmune disease is common in common variable immunodeficiency.2 Most patients will present in the first instance to their general practitioner, who must be alert to the possibility and seek an appropriate second opinion. Treatment is by giving replacement immunoglobulin to compensate for the missing antibodies, using immunoglobulin G prepared from large donor pools and administered by the intramuscular or, more commonly, the intravenous route. Antibiotics and plasma are ineffective alone. Failure to treat adequately leads to progressive structural damage, particularly of sinuses and lungs from recurrent infections3 and to a significant risk of serious invasive infection and early mortality (G P Spickett and T Askew, in preparation). In the United Kingdom these conditions are considerably underdiagnosed compared with Scandinavia. Furthermore, small studies have shown a considerable diagnostic delay -on average about seven years from onset of symptoms to diagnosis4 ( : 2 (7) 8 (29) 12 (43) 13 (46) 113 (46) 14 ( weight whereas 20 used a variable dose determined by the trough immunoglobulin G concentration. Eight immunologists used a per infusion dose of 0-2-0O4 g/kg/infusion whereas seven used doses within the range 0-2-0-6 g/kg/infusion. There was very wide variation of the target trough immunoglobulin G concentration sought by those immunologists using this measure (range <4 g/l to >8 g/l (normal range for serum immunoglobulin G about 6-16 g/l)): some respondents specified more than one target level, presumably indicating that they set the target according to clinical status. It is of concern that six were using target immunoglobulin G concentrations <5 g/l, the desirable threshold in one published study. One immunologist viewed a trough level of <4 g/l as satisfactory despite this being less than 66% of the lower limit of normal. Three immunologists were using follow up intervals of four weeks or greater. Monitoring of treatment by trough immunoglobulin G concentrations was carried out by 25 immunologists, but only 17 regularly measured lung function, a useful marker of the overall adequacy of replacement; 16 immunologists asked patients to keep symptom diaries.
FEEDBACK
All participants were sent an anonymised copy of the analysis of the results, together with a summary of the areas of particular concern, to try and improve their quality of care.
Discussion
This survey highlights the differences in approach to the management of rare group of conditions undertaken by a group of interested specialists and compares it with management standards identified in a multidisciplinary consensus. Although overall there was good agreement with the standards identified, a minority of specialists were offering care that deviated significantly from the agreed standards in a way that may prejudice the quality of care -for instance, by inappropriate use of intramuscular immunoglobulin, unduly low target concentration of immunoglobulin for treatment, and lack of specialist follow up. Patients will also be inconvenienced by lack of access to facilities for self treatment at home, lack of supportive information and information about a patient support society.
A problem with postal surveys is that they analyse "reported practice," which may differ from actual practice. However, all the participants in this survey agreed to participate in an extensive project to obtain clinical and outcome information on patients with antibody deficiency. That project is nearing completion and will provide information, by centre, of the quality of patient care. The project involves a review of the case notes of all identified patients with antibody deficiency and is being carried out in conjunction with efforts to produce an up to date register of patients with all types of immune deficiencies (G P Spickett and T Askew, unpublished). An interim analysis carried out on 392 records shows that significant numbers of patients have chronic complications, particularly bronchiectasis and sinusitis. Complications continue to develop after referral to immunologists. It also confirms that the delay from onset of clear symptoms to referral to an immunologist is over 10 years. The final analysis is expected to have over 1000 records and will relate complications to delay in diagnosis, treatment, and type of treatment.
Although all immunologists in this survey measured serum immunoglobulins, the number routinely carrying out further tests was below 60%, despite evidence that significant immunodeficiency may occur in the presence of normal immunoglobulins.6 The consensus document indicates that it is appropriate for patients with suspected antibody deficiency to have lymphocyte surface markers, immunoglobulin G subclasses and specific antiviral and antibacterial antibodies measured, unless immunoglobulin concentrations are so low as to render the tests unnecessary. Thus the consensus standard was not being met in all centres. offering a treatment that is probably less than optimum: if they find that the outcome is satisfactory then the data need to be published and compared with existing data.
This survey has drawn attention to the difficulties of ensuring uniformity of treatment for rare diseases even between specialists. Although the approach taken by immunologists overall is generally uniform, there is a minority whose practice is at variance with their peers. The problems of poor quality care will be highlighted by the other part of this audit project which entails collecting data on morbidity and mortality in antibody deficiency. Dealing with the problem of inadequate care of patients by non-specialists will be difficult until the specialists themselves have ensured compliance with all the standards of the consensus document. We hope that the feedback of the survey data to the participants will highlight to individual immunologists where their practice differs from that of their peers. This survey is the first attempt at auditing the clinical performance of immunologists, but there is no formal mechanism and no regular national audit forum. The current project is funded only for a fixed period. The question of who sets standards of care for rare diseases and how they are monitored for appropriateness and for implementation has not been addressed in any systematic way but is worth study, as such diseases often involve expensive tertiary care.
By agreement, the consensus panel identified centres where it believes sufficient expertise exists, based on numbers of patients treated, to manage antibody deficiency effectively.5 However, this will not be effective in improving patient care unless purchasing authorities are prepared to take notice and direct their contracts accordingly. The NHS Executive has produced guidance on contracting for specialist services,'4 but in many regions the recommendations are not fully implemented. Designation of specialist centres, with appropriate staffing and funding, is required to deal appropriately with rare and chronic diseases.
